CN110615808B - 一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 - Google Patents
一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 Download PDFInfo
- Publication number
- CN110615808B CN110615808B CN201910438983.XA CN201910438983A CN110615808B CN 110615808 B CN110615808 B CN 110615808B CN 201910438983 A CN201910438983 A CN 201910438983A CN 110615808 B CN110615808 B CN 110615808B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- cyclopropyl
- preparation
- fluorescent compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000007850 fluorescent dye Substances 0.000 title abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 239000000523 sample Substances 0.000 claims abstract description 18
- 102100024748 E3 ubiquitin-protein ligase UHRF2 Human genes 0.000 claims abstract description 9
- 101710131422 E3 ubiquitin-protein ligase UHRF2 Proteins 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 20
- -1 N, N-dimethylamino Chemical group 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 5
- 239000012024 dehydrating agents Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910003827 NRaRb Inorganic materials 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 19
- 238000003384 imaging method Methods 0.000 abstract description 8
- 230000005284 excitation Effects 0.000 abstract description 6
- 238000013399 early diagnosis Methods 0.000 abstract description 5
- 238000002189 fluorescence spectrum Methods 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 4
- 239000003068 molecular probe Substances 0.000 abstract description 3
- 238000000295 emission spectrum Methods 0.000 abstract description 2
- 238000002284 excitation--emission spectrum Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 17
- 239000000178 monomer Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- XRWRBHCGNJODJX-UHFFFAOYSA-N 1-cyclopropyl-2-(4-ethylphenyl)butane-1,3-dione Chemical compound C1(CC1)C(C(C(C)=O)C1=CC=C(C=C1)CC)=O XRWRBHCGNJODJX-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- JYHAOJGBXVCDOC-GGWOSOGESA-N (2e,4e)-5-[4-(dimethylamino)phenyl]penta-2,4-dienal Chemical compound CN(C)C1=CC=C(\C=C\C=C\C=O)C=C1 JYHAOJGBXVCDOC-GGWOSOGESA-N 0.000 description 3
- OOLSRHZMXAYDFB-UHFFFAOYSA-N 1-ethyl-4-iodobenzene Chemical compound CCC1=CC=C(I)C=C1 OOLSRHZMXAYDFB-UHFFFAOYSA-N 0.000 description 3
- NXVSLJTYTSUICQ-UHFFFAOYSA-N 3-[6-(diethylamino)pyridin-3-yl]prop-2-enal Chemical compound CCN(CC)C1=NC=C(C=C1)C=CC=O NXVSLJTYTSUICQ-UHFFFAOYSA-N 0.000 description 3
- JUTDYBQRBHFSFI-UHFFFAOYSA-N 5-[6-(diethylamino)pyridin-3-yl]penta-2,4-dienal Chemical compound CCN(CC)C1=NC=C(C=C1)C=CC=CC=O JUTDYBQRBHFSFI-UHFFFAOYSA-N 0.000 description 3
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ARGUZFSDKOFCOE-UHFFFAOYSA-N 1-cyclopropyl-2-(3,5-dimethylphenyl)butane-1,3-dione Chemical compound CC1=CC(=CC(=C1)C(C(=O)C)C(=O)C2CC2)C ARGUZFSDKOFCOE-UHFFFAOYSA-N 0.000 description 2
- JDKQMYPXLQBPNW-UHFFFAOYSA-N 1-cyclopropyl-2-(3-methylphenyl)butane-1,3-dione Chemical compound CC1=CC(=CC=C1)C(C(=O)C)C(=O)C2CC2 JDKQMYPXLQBPNW-UHFFFAOYSA-N 0.000 description 2
- KLCGMDWRXACELA-UHFFFAOYSA-N 1-cyclopropylbutane-1,3-dione Chemical compound CC(=O)CC(=O)C1CC1 KLCGMDWRXACELA-UHFFFAOYSA-N 0.000 description 2
- SWXBDNMDLIIGLI-UHFFFAOYSA-N 3-(3,5-dimethylphenyl)hexane-2,4-dione Chemical compound CCC(=O)C(C1=CC(=CC(=C1)C)C)C(=O)C SWXBDNMDLIIGLI-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- ZLMKEENUYIUKKC-UHFFFAOYSA-N 1-iodo-3,5-dimethylbenzene Chemical group CC1=CC(C)=CC(I)=C1 ZLMKEENUYIUKKC-UHFFFAOYSA-N 0.000 description 1
- VLCPISYURGTGLP-UHFFFAOYSA-N 1-iodo-3-methylbenzene Chemical compound CC1=CC=CC(I)=C1 VLCPISYURGTGLP-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- VVECGOCJFKTUAX-UHFFFAOYSA-N 2-[3-fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=C(F)C(NC)=CC=C1C1=NC2=CC=C(O)C=C2S1 VVECGOCJFKTUAX-UHFFFAOYSA-N 0.000 description 1
- NCWZOASIUQVOFA-NSCUHMNNSA-N 4-[(e)-2-[4-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]phenyl]ethenyl]-n-methylaniline Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCCF)C=C1 NCWZOASIUQVOFA-NSCUHMNNSA-N 0.000 description 1
- JYHAOJGBXVCDOC-UHFFFAOYSA-N 5-[4-(dimethylamino)phenyl]penta-2,4-dienal Chemical compound CN(C)C1=CC=C(C=CC=CC=O)C=C1 JYHAOJGBXVCDOC-UHFFFAOYSA-N 0.000 description 1
- PVUKGNBRJFTFNJ-UHFFFAOYSA-N 6-bromopyridine-3-carbaldehyde Chemical compound BrC1=CC=C(C=O)C=N1 PVUKGNBRJFTFNJ-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- YNDIAUKFXKEXSV-CRYLGTRXSA-N florbetapir F-18 Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCC[18F])N=C1 YNDIAUKFXKEXSV-CRYLGTRXSA-N 0.000 description 1
- 229940113298 flutemetamol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- NDOGLIPWGGRQCO-UHFFFAOYSA-N hexane-2,4-dione Chemical compound CCC(=O)CC(C)=O NDOGLIPWGGRQCO-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- RUKJCCIJLIMGEP-UHFFFAOYSA-N p-dimethylaminocinnamaldehyde Chemical compound CN(C)C1=CC=C(C=CC=O)C=C1 RUKJCCIJLIMGEP-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- AVFBYUADVDVJQL-UHFFFAOYSA-N phosphoric acid;trioxotungsten;hydrate Chemical compound O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O AVFBYUADVDVJQL-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000008625 synaptic signaling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1096—Heterocyclic compounds characterised by ligands containing other heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种与Aβ寡聚体具有亲和力的荧光化合物,并公开了其制备方法以及应用。本发明获得的荧光化合物最大激发和荧光发射光谱值分别在550~560nm和600~700nm之间,大部分的化合物的发射光谱值>650nm;适合用于阿尔茨海默氏病可溶性Aβ寡聚体成像的近红外荧光分子探针的特性,适合应用于制备NIRF探针,特别是靶向可溶性Aβ寡聚体的NIRF探针,该探针可用于阿尔兹海默症的早期诊断。
Description
技术领域
本发明属于特异性分子识别诊断试剂领域,具体涉及一种与Aβ寡聚体具有亲和力的荧光化合物及制备与应用。
背景技术
阿尔茨海默病(Alzheimer’s disease,AD)是最常见的神经***退行性疾病,临床表现为认知和记忆功能下降,日常生活能力减退,并伴有各种神经精神症状和行为障碍。全球的AD患者约4700万,由于人口老龄化,到2050年,人数预计将达到1.31亿。病因迄今未明。目前尚有效的药物或方法逆转AD的进程,只能部分改善临床症状.临床上主要通过评价患者的认知能力损伤来诊断,而此时确诊患者多已进入病程的中晚期而延误了治疗。缺乏有效的检测手段已成为AD早期诊断和治疗的重大障碍。因此发展一种有效可靠的诊断手段,对AD进行早诊断、早治疗以提高病患的存活率,在临床上具有较高的应用价值。
在AD患者脑中,β-淀粉样蛋白斑块在脑中沉积是AD最为显著的病理性标志之一。然而越来越多的研究表明,Aβ斑块的多少与AD的严重程度缺乏相关性。大脑中有斑块不一定会发展成AD。与不溶性的沉淀斑相比可溶性的Aβ寡聚体要比斑块有着更强的神经毒性,一方面体积较小的Aβ寡聚体与神经元接触面积大,能进入到突触间隙,聚集在细胞膜和脂质阀上,导致膜***和破坏;另一方面,Aβ寡聚体结合细胞膜上的受体,诱发内吞进入细胞中,影响突触信号传导,最终导致突触丢失,记忆受损。此外,Aβ寡聚体还能导致非正常去极化线粒体细胞膜,释放细胞凋亡因子细胞色素C,而这被证明与突触功能障碍和记忆受损密切相关。
过去的数几十年里,已有较多具有放射性针对Aβ斑块的分子探针进入临床试验阶段,并有相关PET成像试剂上市(Florbetapir、Florbetaben、Flutemetamol),然而放射性显像方法的应用也受一些因素限制,比如放射性元素所发出的射线对人体具有一定的辐射损伤、需要昂贵的仪器和专业的人员。相比较之下,光学成像具有安全无放射性、数据采集时间短以及成本低廉等诸多优势,近年在医学诊断等中的应用受到广泛重视。尤其是近红外荧光成像技术,其优点在于:(1)灵敏度高,可实现微弱信号的检测;(2)检测安全,不接触放射性元素;(3)无需耗时,数据采集过程中实时成像;(4)成本适中,无需昂贵的设备和技术高超的人员;(5)NIRF探针结合了靶蛋白后,荧光特性(如荧光强度、发射波长和量子产率)发生显著改变,无需连接报告基团,就可以直接检测探针和靶蛋白的相互作用。目前靶向不可溶性的板块的探针已有较多成功的研究工作,如CRANAD-2、AOI987、NIAD-16、DANIR-2C和DBA-SLOH等。但是,设计专一性靶向可溶性Aβ寡聚体的NIRF探针具有很大的难度。
发明内容
发明目的:针对上述现有技术存在的技术问题,本申请提供了一种可选择性地与可溶性Aβ寡聚体结合的荧光化合物,并提供了其制备方法与应用。
技术方案:本发明公开了一种如式I所示的化合物,
其中,R1为-NRaRb,其中,Ra和Rb独立地选自为氢、C1-6烷基或C1-6羟烷基,但Ra和Rb不同时为氢;
R2为苯基、C3-6环烷基或C1-4烷基;
R3为氢、C1-6烷基,其中R3表示单取代或二取代(例如3,5-位二取代);
X表示C原子或者N原子;
n=1、2、3、4。
进一步的,Ra、Rb和R3中所述的C1-6烷基优选C1-4烷基,进一步的,所述的C1-4烷基优选甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基。
进一步的,R2中所述的C3-6环烷基优选环丙基、环丁基、环戊基或环己基。更进一步的,R2优选氢、3-乙基或2,5-二甲基。
R1优选N,N-二甲基氨基、N,N-二乙基氨基、N,N-甲基羟乙氨基。
优选的,本申请所述化合物选自如下任一化合物:
本发明还公开了如式I所示化合物的制备方法,包括以下步骤:有机溶剂中,在碱的催化下,脱水剂的存在下,将如式3所示的化合物与如式4所示的化合物进行缩合反应,反应式如下:
所述有机溶剂可为本领域此类反应常规的有机溶剂,优选苯类溶剂,其中,苯类溶剂优选甲苯。优选式3与式4所示化合物的体积摩尔比为1∶1。
所述碱可为本领域此类反应常规的碱,优选四氢异喹啉(即1,2,3,4-四氢异喹啉)。所述的碱的用量可不做具体限定,一般为催化量,较佳地其与如式3所示的化合物的摩尔比为0.1-0.9∶1,更佳地为0.1-0.3∶1。
所述脱水剂可为本领域此类反应常规的脱水剂,优选冰乙酸。所述的脱水剂的用量可为本领域此类反应常规的用量,较佳地其与如式3所示的化合物的摩尔比为0.1-0.9∶1,更佳地为0.2-0.5∶1。
所述的如式3所示的化合物与如式4所示的化合物的摩尔比可不作具体限定,只要不影响反应进行即可,较佳地为1∶1。
所述的缩合反应的温度可为本领域此类反应常规的温度,较佳地为室温(0-30℃)。所述的缩合反应的进程可采用本领域有机合成反应常规的检测方法进行监测(例如TLC、GC、HPLC或NMR等),通常以如式4所示的化合物消失时作为反应的终点。所述的缩合反应的时间较佳地为2-6小时(例如3小时)。
进一步优选的,上述式4所示的化合物可以通过以下方法步骤制备得到:
本发明还公开了所述化合物在制备NIRF探针中的应用。
进一步的,所述化合物在制备靶向可溶性Aβ寡聚体的NIRF探针中的应用。
所述探针可用于阿尔兹海默症的早期诊断。
有益效果:本发明公开了一种结构新颖的荧光化合物,并进一步公开了其制备方法,本发明获得的荧光化合物最大激发和荧光发射光谱值分别在550~560nm和600~700nm之间,大部分的化合物的发射光谱值>650nm;适合用于阿尔茨海默氏病可溶性Aβ寡聚体成像的近红外荧光分子探针的特性;本申请还通过体内外实验证实,其体内代谢稳定、与可溶性Aβ=寡聚体具有很好的亲和力、活体成像结果表明能够对4个月大的AD老鼠脑内淀粉样蛋白进行近红外荧光显像,能够区分4个月大的AD老鼠和正常老鼠,由此可见,其适合应用于制备NIRF探针,特别是靶向可溶性Aβ寡聚体的NIRF探针,该探针可用于阿尔兹海默症的早期诊断。
附图说明
图1是本发明最优选荧光化合物与Aβ42单体、Aβ40单体、Aβ42寡聚体、聚合物、BSA混合前后的荧光发射光谱;
图2为本发明最优选荧光化合物的MTT细胞活力测试图;
图3为本发明最优选荧光化合物与Aβ42寡聚体的结合常数;
图4为本发明最优选荧光化合物与小鼠血清的稳定性;
图5是最优选荧光化合物的活体小动物近红外成像图;
图6是透射电子显微镜成像图。
具体实施方式
下面结合具体实施例对本发明进行详细说明。
本发明式I所示化合物可通过以下步骤制备得到:
实施例1:6-二乙胺基-3-吡啶醛的合成
依次将6.5mL DMF、2-溴-5-醛基吡啶(1200mg,6.45mmol)、二乙胺(6mL,58.06mmol)加入35ml的封管中,磁力搅拌,反应温度90℃,反应17h,TLC监测(PE:EA=6:1)。后处理:二氯甲烷(DCM)萃取(3×10ml),合并有机层,用饱和食盐水洗涤(3×10ml),无水Na2SO4干燥。减压浓缩后柱层析,洗脱剂为PE:EA=10:1(v/v),得淡黄色固体782mg,收率68%。1H NMR(300MHz,,Chloroform-d)δ:9.68(s,1H),8.48-8.47(d,J=2,1H),7.85-7.81(dd,J=10Hz,1H),6.48-6.45(d,J=15Hz,1H),3.58-3.51(m,4H),1.19-1.15(t,6H)
化学式如下:
实施例2:3-(6-(二乙基氨基)吡啶-3-基)丙烯醛的合成
加入6-二乙胺基-3-吡啶醛(400mg,2.24mmol),无水THF(16ml),搅拌后就加入2-[(1,3)-二氧戊环-2-基]-甲基三苯基溴化瞵(1900mg,4.48mmol),分两次加入NaH(215mg,8.96mmol),最后加入18-冠醚-6(118mg.0.048mmol))。室温反应24h.TLC监测(PE:EA=6:1)。后处理:反应液冷却至室温后,抽滤,滤液用***萃取(3×10ml),合并有机层,用饱和食盐水洗涤(3×10ml),无水Na2SO4干燥。浓缩后加入THF和10%盐酸(42ml/17ml)的混合溶液,搅拌5h,加入10%NaOH溶液调中性。接着用DCM萃取(3×10ml),合并有机层,用饱和食盐水洗涤(3×10ml),无水Na2SO4干燥。浓缩(柱层析,洗脱剂为PE:EA=10:1,真空干燥,得橙红色油状物固体137mg,收率30%。
1H NMR(300MHz,Chloroform))δ9.60(d,J=7.8Hz,1H),8.29(s,1H),7.66(d,J=9.2Hz,1H),7.35(d,J=15.6Hz,1H),6.59–6.44(m,2H),3.58(q,J=7.3Hz,4H),1.22(t,J=7.3Hz,6H).
化学式如下:
实施例3:5-(4-(二甲基氨基)苯基)戊-2,4-二烯醛的合成
方法同实施例2,所不同的是用3-(4-(二甲基氨基)苯基)丙烯醛代替6-二乙胺基-3-吡啶醛,得到棕黄色固体产物,收率:41%
1H NMR(300MHz,Chloroform-d)δ9.50(dt,J=7.1,0.9Hz,1H),7.46–7.39(m,2H),7.15(ddd,J=14.3,7.3,1.0Hz,1H),7.05(d,J=14.0Hz,1H),6.82–6.68(m,3H),6.09(ddd,J=14.1,7.2,0.7Hz,1H),3.01(s,5H).化学式如下:
实施例4:5-(6-(二乙基氨基)吡啶-3-基)戊-2,4-二烯醛的合成
方法同实施例2,所不同的是用3-(6-(二乙基氨基)吡啶-3-基)丙烯醛代替6-二乙胺基-3-吡啶醛,得到橙色固体产物,收率:28%.
1H NMR(300MHz,Chloroform-d)δ9.50(d,J=7.1,0.9Hz,1H),8.35(d,J=1.9Hz,1H),7.49(dd,J=8.4,1.8Hz,1H),7.14(ddd,J=14.2,7.3,1.0Hz,1H),7.00(d,J=14.1Hz,1H),6.81(ddt,J=14.1,7.3,0.8Hz,1H),6.73(d,J=8.4Hz,1H),6.13(ddd,J=14.3,7.1,0.7Hz,1H),3.47(q,J=7.2Hz,4H),1.17(t,J=7.2Hz,6H).
化学式如下:
实施例5:1-环丙基-2-(4-乙基苯基)-1,3-丁二酮的合成
依次将无水K2CO3(2.76g,20mmol)、L-脯氨酸(230mg,2mmol)、CuI(95mg,0.5mmol)、加入100ml三颈反应瓶中,N2保护,通过注射器向其中加入DMSO(20ml)、1-环丙基-1,3,-丁二酮(0.59ml,5mmol)、1-乙基-4-碘苯(0.724ml,5mmol)磁力搅拌,反应温度90℃,反应18h,TLC监测(PE:EA=20:1)。后处理:反应液冷却至室温后,抽滤,滤液用乙酸乙酯(EA)萃取(3×10ml),合并有机层,用饱和食盐水洗涤(3×10ml),无水Na2SO4干燥。浓缩后柱层析,洗脱剂为PE:EA=70:1,真空干燥,得黄色固体160mg,收率14%。
1H NMR(300MHz,Chloroform-d)δ16.88(s,1H),7.27–7.09(m,4H),2.67(q,J=7.6Hz,2H),1.71(tt,J=8.0,4.5Hz,1H),1.48(q,J=3.9Hz,2H),1.46–1.31(m,6H),1.04(dq,J=7.6,3.9Hz,2H)
化学式如下:
实施例6:1-环丙基-2-(3,5-二甲基苯基)-1,3-丁二酮的合成
方法同实施例5,所不同的是用5-碘间二甲苯代替1-乙基-4-碘苯,得到黄色固体产物,收率:23%。
1H NMR(300MHz,Chloroform-d)δ7.08(s,1H),6.94(s,2H),2.05(s,6H),1.89(s,3H),1.70(tt,J=8.0,4.5Hz,1H),1.49(q,J=3.9Hz,2H),1.05(dq,J=7.6,3.9Hz,2H).
化学式如下:
实施例7:1-环丙基-2-(间甲苯基)丁烷-1,3-二酮的合成
方法同实施例5,所不同的是用1-碘-3-甲基苯代替1-乙基-4-碘苯,得到黄色固体产物,收率:30%。
1H NMR(300MHz,Chloroform-d)δ7.08(s,1H),6.94(s,2H),2.05(s,3H),1.89(s,3H),1.70(tt,J=8.0,4.5Hz,1H),1.49(q,J=3.9Hz,2H),1.05(dq,J=7.6,3.9Hz,2H).
化学式如下:
实施例8:3-(3,5-二甲基苯基)己烷-2,4-二酮的合成
方法同实施例5,所不同的是用己烷-2,4-二酮代替1-环丙基-1,3,-丁二酮,得到黄色固体产物,收率:30%。
1H NMR(300MHz,Chloroform-d)δ16.55(s,1H),7.49(d,J=9.0Hz,1H),6.79(d,J=1.5Hz,2H),2.45–2.35(m,8H),1.35–1.20(m,6H).
化学式如下:
实施例9:4-环丙基-5-(4-乙基苯基)-2,2-二氟-6-甲基-二氧杂硼烷的合成
将1-环丙基-2-(4-乙基苯基)-1,3-丁二酮(160mg,0.78mmol)、硼酸三丁酯(0.47ml,1.57mmol)加入25ml反应瓶中,橡胶塞封口并插上N2气球针管,缓慢滴加三氟化硼***(0.47ml,1.57mmol),室温搅拌5h,TLC监测(PE:EA=6:1)。后处理:缓慢加入水淬灭三氟化硼***,析出白色固体,继续加入石油醚析出更多的固体,抽滤得白色固体153mg,收率78%。
1H NMR(300MHz,Chloroform-d)δ16.88(s,1H),7.27–7.09(m,4H),2.67(q,J=7.6Hz,2H),1.71(tt,J=8.0,4.5Hz,1H),1.48(q,J=3.9Hz,2H),1.46–1.31(m,6H),1.04(dq,J=7.6,3.9Hz,2H).
化学式如下:
实施例10:4-环丙基-5-(3,5-二甲基苯基)-2,2-二氟-6-甲基二氧杂硼烷的合成
方法同实施例9,所不同的是用1-环丙基-2-(3,5-二甲基苯基)-1,3-丁二酮代替1-环丙基-2-(4-乙基苯基)-1,3-丁二酮,得到白色固体产物,收率:80%。
1H NMR(300MHz,Chloroform-d)δ7.08(s,1H),6.94(s,2H),2.05(s,6H),1.89(s,3H),1.70(tt,J=8.0,4.5Hz,1H),1.49(q,J=3.9Hz,2H),1.05(dq,J=7.6,3.9Hz,2H)
化学式如下:
实施例11:4-环丙基-2,2-二氟-6-甲基-5-(间甲苯基)-二氧杂硼烷的合成方法同实施例9,所不同的是用1-环丙基-2-(间甲苯基)丁烷-1,3-二酮代替1-环丙基-2-(4-乙基苯基)-1,3-丁二酮,得到白色固体产物,收率:81%。
1H NMR(300MHz,Chloroform-d)δ7.08(s,1H),6.94(s,2H),2.05(s,3H),1.89(s,3H),1.70(tt,J=8.0,4.5Hz,1H),1.49(q,J=3.9Hz,2H),1.05(dq,J=7.6,3.9Hz,2H)
化学式如下:
实施例12:5-(3,5-二甲基苯基)-4-乙基-2,2-二氟-6-甲基--二氧杂硼烷的合成
方法同实施例9,所不同的是用3-(3,5-二甲基苯基)己烷-2,4-二酮代替1-环丙基-2-(4-乙基苯基)-1,3-丁二酮,得到白色固体产物,收率:85%。1H NMR(300MHz,Chloroform-d)δ7.14(d,J=7.6Hz,2H),6.45(d,J=9.1Hz,2H),2.76(q,J=7.6Hz,2H),2.37(q,J=7.5Hz,2H),1.34(t,J=7.6Hz,3H),1.34–1.19(m,6H).
化学式如下:
实施例13:5-(2-(6-环丙基-5-(4-乙基苯基)-2,2-二氟-二氧杂环-4-基)乙烯基)-N,N-二乙基-2-胺的合成
向25ml三颈烧瓶中依次加入4-环丙基-5-(4-乙基苯基)-2,2-二氟-6-甲基-二氧杂硼烷(1mmol,277mg),甲苯(6ml)溶解后,再依次加入6-二乙胺基-3-吡啶醛(204mg,1mmol),乙酸(37μl,0.648mmol),四氢异喹啉(27μl,0.216mmol,),磁力搅拌,室温反应6h。TLC板监测(DCM),反应完毕,旋蒸除去溶剂得粗品,过柱纯化(洗脱剂:DCM),得到红色粉末状产物收率187mg,40.4%.
1H NMR(300MHz,Chloroform-d)δ8.25(d,J=2.4Hz,1H),7.94(d,J=15.3Hz,1H),7.39(dd,J=9.1,2.5Hz,1H),7.34–7.16(m,4H),6.42(d,J=9.1Hz,1H),6.19(d,J=15.3Hz,1H),3.55(q,J=7.1Hz,4H),2.74(q,J=7.6Hz,2H),1.68(tt,J=8.1,4.5Hz,1H),1.47(q,J=3.9Hz,2H),1.32(t,J=7.6Hz,3H),1.19(t,J=7.1Hz,6H),1.03(dq,J=7.6,3.8Hz,2H).HRMS(ESI)C25H29BF2N2O2,[M+H]+calculated=439.2363;found=439.2379.
化学式如下:
实施例14:4-(6-环丙基-5-(4-乙基苯基)-2,2-二氟-2二氧杂环-4-基)丁-1,3-二烯-1-基)-N,N-二乙基吡啶-2-胺的合成
方法同实施例13,所不同的是用3-(6-(二乙基氨基)吡啶-3-基)丙烯醛代替6-二乙胺基-3-吡啶醛,得到绿色固体产物,收率:40%。
1H NMR(400MHz,Chloroform-d)δ8.21(d,J=2.4Hz,1H),7.84(dd,J=14.5,11.5Hz,1H),7.55(dd,J=9.1,2.5Hz,1H),7.32(d,J=8.1Hz,2H),7.22(d,J=8.0Hz,2H),6.95(d,J=15.2Hz,1H),6.61(dd,J=15.2,11.5Hz,1H),6.45(d,J=9.0Hz,1H),3.57(q,J=7.1Hz,4H),2.76(q,J=7.6Hz,2H),1.72–1.66(m,1H),1.50(p,J=3.9Hz,2H),1.34(t,J=7.6Hz,3H),1.21(t,J=7.1Hz,6H),1.05(dt,J=7.5,3.8Hz,2H).
化学式如下:
实施例15:4-4-(6-环丙基-5-(4-乙基苯基)-2,2-二氟-2-二氧杂环-4-基)丁-1,3-二烯-1-基)-N,N-二甲基苯胺的合成
方法同实施例13,所不同的是用5-(4-(二甲基氨基)苯基)戊-2,4-二烯醛代替6-二乙胺基-3-吡啶醛,得到绿色固体产物,收率:39%。
1H NMR(300MHz,CDCl3)δ7.88(dd,J=14.4,11.6Hz,1H),7.38(d,J=9.4Hz,4H),7.25(d,J=7.7Hz,2H),7.02(d,J=15.1Hz,1H),6.69(t,J=10.3Hz,3H),5.90(d,J=14.5Hz,1H),3.07(s,6H),2.79(q,J=7.6Hz,2H),1.79–1.64(m,1H),1.52(t,J=3.9Hz,2H),1.37(t,J=7.7Hz,3H),1.07(dq,J=7.7,3.8Hz,2H).HRMS(ESI)C26H28BF2NO2,[M+H]+calculated=435.2289;found=436.2267.
化学式如下:
实施例16:5-6-(6-环丙基-5-(4-乙基苯基)-2,2-二氟-2-二氧杂环-4-基)六-1,3,5-三烯-1-基)-N,N-二乙基吡啶-2-胺的合成
方法同实施例13,所不同的是用5-(6-(二乙基氨基)吡啶-3-基)戊-2,4-二烯醛代替6-二乙胺基-3-吡啶醛,得到绿色固体产物,收率:21%。
1H NMR(300MHz,Chloroform-d)δ8.22(d,J=9.3Hz,1H),7.92–7.62(m,1H),7.55(d,J=8.9Hz,1H),7.42–7.15(m,4H),7.01–6.44(m,4H),6.41–6.02(m,1H),5.87(d,J=14.4Hz,1H),3.67–3.48(m,3H),2.75(q,J=7.6Hz,2H),1.69(s,1H),1.51(s,2H),1.31–1.16(m,9H),1.07(s,2H).
化学式如下:
实施例17:4-4-(6-环丙基-5-(3,5-二甲基苯基)-2,2-二氟-2-二氧杂环-4-基)丁-1,3-二烯-1-基)-N,N-二甲基苯胺的合成
向25ml三颈烧瓶中依次加入4-环丙基-5-(3,5-二甲基苯基)-2,2-二氟-6-甲基-二氧杂硼烷(1mmol,277mg),甲苯(6ml)溶解后,再依次加入6-二乙胺基-3-吡啶醛(204mg,1mmol),乙酸(37μl,0.648mmol),四氢异喹啉(27μl,0.216mmol,),磁力搅拌,室温反应6h。TLC板监测(DCM),反应完毕,旋蒸除去溶剂得粗品,过柱纯化(洗脱剂:DCM),得到红色粉末状产物收率187mg,40.4%.
1H NMR(500MHz,Chloroform-d)δ8.32(d,J=2.4Hz,1H),7.97(d,J=15.4Hz,1H),7.55(d,J=9.0Hz,1H),7.11(s,1H),6.85(d,J=1.5Hz,2H),6.60(s,1H),6.25(d,J=15.4Hz,1H),3.68(s,4H),2.46–2.36(m,8H),1.29(t,J=7.1Hz,6H),1.18(t,J=7.4Hz,3H).HRMS(ESI)C24H29BF2N2O2,[M+H]+calculated=427.2363;found=427.2382
化学式如下:
实施例18:4-4-(6-环丙基-5-(3,5-二甲基苯基)-2,2-二氟-2-二氧杂环-4-基)丁-1,3-二烯-1-基)-N,N-二甲基苯胺的合成
方法同实施例17,所不同的是用5-(4-(二甲基氨基)苯基)戊-2,4-二烯醛
代替6-二乙胺基-3-吡啶醛,得到绿色固体产物,收率:39%。1H NMR(500MHz,Chloroform-d)δ7.45–7.35(m,3H),7.04(d,J=15.5Hz,1H),6.99–6.92(m,3H),6.75–6.68(m,2H),6.54(ddd,J=15.5,7.4,1.0Hz,1H),6.04(dd,J=14.7,7.4Hz,1H),3.71(p,J=6.4Hz,1H),3.03(s,5H),2.31(s,6H),1.39(d,J=6.4Hz,4H).
化学式如下:
实施例19:4-4-(6-环丙基-5-(3,5-二甲基苯基)-2,2-二氟-2-二氧杂环-4-基)丁-1,3-二烯-1-基)-N,N-二甲基苯胺的合成
方法同实施例17,所不同的是用5-(4-(二甲基氨基)苯基)戊-2,4-二烯醛代替6-二乙胺基-3-吡啶醛,得到绿色固体产物,收率:35%。
1H NMR(500MHz,Chloroform-d)δ8.31(d,J=1.9Hz,1H),7.49(dd,J=8.4,1.9Hz,1H),7.43–7.33(m,2H),7.01–6.94(m,3H),6.69(d,J=8.5Hz,1H),6.59(ddd,J=14.1,7.3,0.9Hz,1H),6.21(dd,J=14.7,7.4Hz,1H),3.72(p,J=6.4Hz,1H),3.47(q,J=7.2Hz,4H),2.31(s,6H),1.39(d,J=6.4Hz,4H),1.10–1.03(m,6H).
化学式如下:
实施例20:5-6-(6-环丙基-5-(3,5-二甲基苯基)-2,2-二氟-2-二氧杂环-4-基)六-1,3,5-三烯-1-基)-N,N-二乙基吡啶-2-胺的合成
方法同实施例17,所不同的是用5-(6-(二乙基氨基)吡啶-3-基)戊-2,4-二烯醛代替6-二乙胺基-3-吡啶醛,得到绿色固体产物,收率:21%。
1H NMR(500MHz,Chloroform-d)δ8.29(d,J=1.9Hz,1H),7.43(dd,J=8.4,1.8Hz,1H),7.40–7.32(m,1H),7.31(d,J=14.0Hz,1H),7.00–6.93(m,3H),6.72–6.62(m,2H),6.56–6.39(m,3H),3.71(p,J=6.4Hz,1H),3.47(q,J=7.3Hz,4H),2.31(s,6H),1.39(d,J=6.5Hz,4H),1.10–1.03(m,6H).
化学式如下:
下面是实施例15制备所得化合物(I)(4-4-(6-环丙基-5-(4-乙基苯基)-2,2-二氟-2-二氧杂环-4-基)丁-1,3-二烯-1-基)-N,N-二甲基苯胺)的生物活性研究。
采用F-4500荧光分光光度计在PBS(pH 7.4)条件下分别测试目标化合物(I)、目标化合物(I)与Aβ42单体作用后、Aβ42寡聚体和Aβ4寡聚体作用后的荧光强度值。
实验方法:
Aβ42/Aβ40单体的制备:购买的Aβ42/Aβ40单体(DgPeptides Co,Ltd.,HangZhouCity,China))经HPLC进一步纯化后储存于六氟异丙醇(HFIP)中。粒度经由Zetasizer Nano(Malvern)测定。10μL的Aβ42/Aβ40单体(25μM)储备液经真空离心挥干溶剂,重新溶于1mL蒸馏水中。经粒度测试该Aβ42/Aβ40单体的水溶液粒度大小低于仪器所能测定的最低值,即无大粒径颗粒。
Aβ42寡聚体的制备:将Aβ42单体(0.1mg)溶于40μL六氟异丙醇(Hexafluoroisopropanol,HFIP),室温孵育10-20min,然后加入886μL双蒸水,室温孵育20min。14,000x G离心机离心15min,移取上清液并用N2吹干HFIP,22℃搅拌24h。
采用荧光分光光度计(日立F-4600),参数设置:狭缝宽度(激发/发射)=10/10;PMT=700V;扫描速度=1200nm/min;响应速度为自动模式。测定化合物最大激发波长及最大发射波长;后在最大激发波长下,测定化合物与Aβ蛋白结合后的荧光性质,具体方法如下:
化合物及化合物与Aβ单体的结合实验:将900μL PBS缓冲液加入到1.0mL的比色皿中,进行荧光测定,作为空白对照;将40μL化合物溶液(12.5μM)加入到上述比色皿中,测定化合物自身荧光强度;在上述化合物溶液中加入60μL的Aβ42单体的HFIP溶液(25μM),立即测定荧光性质。
化合物及化合物与Aβ寡聚体的结合实验:将900μL PBS缓冲液(pH7.4)加入到1ml的比色皿中,进行荧光测定,作为空白对照;将40μL化合物溶液(12.5μM)加入到上述比色皿中,测定化合物自身荧光性质;在上述化合物溶液中加入60μL的Aβ42寡聚体溶液(25μM),测定荧光性质。
测定结果如图1所示,根据图示可见,化合物I对Aβ42寡聚体具有选择性,FI(Aβ42寡聚体)/FI(Aβ42聚合物)=2.1倍;FI(Aβ42寡聚体)/FI(Aβ42单体)=7.0;FI(Aβ42寡聚体)/FI(Aβ40单体)=5.25。
透射电子显微镜成像(TEM):选取蛋白培养特定时间点(Aβ42单体2小时;Aβ42寡聚体1天;Aβ42聚合物3天),吸取少量样品转移至铜网格,静置5min,然后滴加2%磷酸钨甲酸,采用日立HT7700透射电镜进行检测成像。结果如图6所示,a为Aβ42单体、b为Aβ42寡聚体、c为Aβ42聚合物。
荧光化合物(I)探针应用于AD转基因小鼠活体成像:将荧光化合物(I)溶液探针(4mg/kg,15%蓖麻油、15%DMSO、70%PBS)由尾静脉注射入AD转基因小鼠(Tg,APP/PS1双转,4月龄)和正常小鼠(WT,C57BL/6 4月龄)体内,在异氟烷的持续麻醉下分别在15min、30min、60min、120min、240min、进行小鼠动物成像图像采集(PerkinElmer,U.S,IVISLuminaXR,激发波长取570nm,发射波长取660nm),分析结果。采用Living ImagingSoftware进行成像结果分析,结果如图5所示,在定量分析表明APP/PS1组相比WT组有更长的保留值,静脉注射荧光化合物(I)后,APP/PS1组分别在第30、60、,120、240、360分钟时分别为WT组的2.10倍,2.00倍,1.87倍和1.74倍。表明荧光化合物(I)能够对4个月的AD小鼠进行检测。
MTT实验方法:1)将对数生长期SH-SY5Y细胞按5*103个/孔的浓度接种于96孔标板内,每孔内体积为100μL。2)置于孵箱内培养12h后,分别加入10μM、1μM和0.1μM的药物(每孔体积为100μL)。3)继续置于孵箱内培养一段时间24后,每孔加入20μL MTT溶液。4)继续孵育4h后将每孔的上清液吸净。5)每孔加入100μL DMSO,放于微型振荡器上振动5min使结晶溶解。6)待结晶完全溶解后将其放于酶标仪上用570nm波长检测。7)将检测后的吸光值整理后按下面的公式计算药物对细胞的生长抑制率。抑制率%=(1-加药组细胞平均吸光值/对照组细胞平均吸光值)×100%。MTT细胞活力测试结果如图2所示,细胞存活率大于90%,荧光化合物(I)毒性小。
结合常数的测定(Kd):荧光化合物(I)和各种浓度的Aβ42寡聚物/聚集体的液进行荧光光谱记录。570nm处的发射读数用于线性回归拟合。通过GraphPad Prism测定结果,如图3所示,Kd(Aβ42寡聚物)=284.3+49.6nM;Kd(Aβ42聚合物)=2309+288nM。
血浆稳定性实验:荧光化合物(I)制成10μM,取50μL配好的溶液加入到装有300μL小鼠血清的EP管中37℃下孵育0min,30min,60min加入500μL冰乙腈离心(5000rmp、15min、4℃)取少量上清液。HPLC分析(乙腈/水=80%:20%,流速1mL/min,紫外检测器320nm。如图4所示,荧光化合物(I)与小鼠血清共孵育60分钟后,化合物仍然含有84%的量。
Claims (10)
2.根据权利要求1所述的化合物,其特征在于,Ra、Rb和R3中所述的C1-6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基。
3.根据权利要求1所述的化合物,其特征在于,R2中所述的C3-6环烷基为环丙基、环丁基、环戊基或环己基。
4.根据权利要求1所述的化合物,其特征在于,R1选自N,N-二甲基氨基、N,N-二乙基氨基、N,N-甲基羟乙氨基。
7.根据权利要求6所述的制备方法,其特征在于,所述有机溶剂为苯类溶剂,所述碱为四氢异喹啉,所述脱水剂为冰乙酸。
8.根据权利要求6所述的制备方法,其特征在于,所述碱与如式3所示的化合物的摩尔比为0.1-0.9∶1,所述脱水剂与如式3所示的化合物的摩尔比为0.1-0.9∶1。
10.权利要求1-5中任一所述化合物在制备NIRF探针中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910438983.XA CN110615808B (zh) | 2019-05-24 | 2019-05-24 | 一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 |
PCT/CN2020/081290 WO2020238375A1 (zh) | 2019-05-24 | 2020-03-26 | 一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910438983.XA CN110615808B (zh) | 2019-05-24 | 2019-05-24 | 一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110615808A CN110615808A (zh) | 2019-12-27 |
CN110615808B true CN110615808B (zh) | 2020-09-08 |
Family
ID=68921301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910438983.XA Active CN110615808B (zh) | 2019-05-24 | 2019-05-24 | 一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110615808B (zh) |
WO (1) | WO2020238375A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805405A (zh) * | 2021-01-18 | 2022-07-29 | 中国科学院上海有机化学研究所 | 一种二氟化硼二酮类化合物、其制备方法及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010017094A2 (en) * | 2008-07-31 | 2010-02-11 | The General Hospital Corporation | CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING |
KR101737872B1 (ko) * | 2015-06-25 | 2017-05-19 | 한국원자력연구원 | 커큐민 유도체, 이의 제조방법 및 이를 포함하는 베타―아밀로이드 플라크 검출용 광음향 영상화제 |
EP3173416B1 (en) * | 2015-11-24 | 2018-11-14 | Université d'Aix Marseille | Borondifluoride complexes of curcuminoid compounds, method of preparation and uses thereof |
CN105622657B (zh) * | 2016-03-09 | 2018-08-21 | 中国药科大学 | 姜黄素衍生物、其制备方法和应用 |
CN109790184B (zh) * | 2016-09-29 | 2021-06-29 | 韩国原子力研究院 | 姜黄素衍生物、其制备方法、以及用于检测β-淀粉样蛋白斑的包含该姜黄素衍生物的光声成像剂 |
-
2019
- 2019-05-24 CN CN201910438983.XA patent/CN110615808B/zh active Active
-
2020
- 2020-03-26 WO PCT/CN2020/081290 patent/WO2020238375A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN110615808A (zh) | 2019-12-27 |
WO2020238375A1 (zh) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111440206B (zh) | 一种近红外荧光探针bodipy类化合物及其制备方法 | |
CN109970751B (zh) | 一种双位点、高灵敏pH荧光探针及其合成与应用 | |
KR101737872B1 (ko) | 커큐민 유도체, 이의 제조방법 및 이를 포함하는 베타―아밀로이드 플라크 검출용 광음향 영상화제 | |
CN106939015B (zh) | 一种丙二醛荧光探针及其制备方法和应用 | |
CN112062755B (zh) | 用于检测天冬氨酰氨肽酶的近红外荧光分子探针、制备方法及用途 | |
CN112142721B (zh) | 一种可靶向线粒体的近红外二区噻喃盐荧光化合物及其制备方法与应用 | |
CN110615808B (zh) | 一种与Aβ寡聚体具有亲和力的荧光化合物及制备方法与应用 | |
CN112552272A (zh) | 香豆素类化合物及其制备方法和应用、药物组合物 | |
WO2009054653A2 (en) | Isoindolones with high binding affinity to beta-amyloid aggregates and fibrils, and its use and preparation method | |
CN111574438B (zh) | 红/近红外AIE探针及其制备方法和在检测Aβ聚集体及其纤维化斑块中的应用 | |
CN114763353A (zh) | 一种基于咪唑并吡啶母核的荧光检测试剂及其对信号分子h2s的检测技术 | |
CN112574239B (zh) | 3-噻唑烯基氟化硼络合二吡咯甲川类化合物及其制备方法和用途 | |
JP6685546B2 (ja) | ドーパミン検出用蛍光物質 | |
CN107118206A (zh) | 一类喹啉‑二吡啶衍生物Zn2+荧光探针及其应用 | |
CN115947777A (zh) | 一种近红外二区荧光化合物及其制备方法与应用 | |
JP6765518B2 (ja) | クルクミン誘導体、その製造方法、及びそれを含むベータ−アミロイドプラーク検出用光音響イメージング剤 | |
CN112794819B (zh) | 一种基于分子异构化机理的可用于铁离子特异性检测的荧光探针的制备方法及应用 | |
CN110669350B (zh) | 一种哌啶基bodipy类红光荧光染料及其制备方法和应用 | |
CN114149420A (zh) | 一种近红外荧光分子探针及其制备方法与应用 | |
CN112321492A (zh) | 监测线粒体自噬的荧光粘度探针及制备和应用 | |
WO2019227526A1 (zh) | 一种荧光标记的核苷酸及其制备方法和用途 | |
CN114213288B (zh) | 一种查尔酮化合物及其制备方法和应用 | |
CN110804046B (zh) | 具有线粒体靶向功能的锌离子比例光声探针与应用 | |
CN114835629B (zh) | 一类咔唑苯并[cd]吲哚鎓盐及其制备方法与应用 | |
CN117820301A (zh) | 靶向线粒体检测过氧化氢的近红外荧光探针及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |